One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
The source uses indexed renal thresholds but prints an unindexed Cockcroft-Gault formula; preserve the distinction rather than silently treating the units as equivalent.
The label mirror uses a daily renal regimen with a timing-dependent post-HD supplement. UCSF also offers a selected post-HD-only strategy, with toxicity, age and low-weight qualifications. The source renal units and exactly-30 boundary do not align automatically.
What to reconcile: Use one complete protocol with the dialysis prescription and ID/pharmacy review. Do not add the label supplement to an institutional post-HD dose or silently equate indexed and unindexed clearance.
Open this note and its source referencesThe label mirror says a supplement is needed within six hours but not needed when the dose is at least six hours before dialysis. The boundary is overlapping as printed.
What to reconcile: Clarify the timing endpoint with the controlling product label and dialysis pharmacist. Do not round an administration time to decide which instruction applies.
Open this note and its source referencesUsual 1 g daily is retained at CrCl 30-49 mL/min and during CRRT. At 10-29, below 10, PD or HD: 500 mg daily; on HD days give toward session end. SLED days use 1 g IV daily, with the ESRD schedule on non-dialysis days. This Canadian institutional protocol is not U.S. labeling.
RDM30-064-ertapenem-1 · Source locator: Sunnybrook - ertapenem renal and replacement-therapy schedule; renal/dosing sections and stated qualifiers
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=ertapenem&s1=RDM30-064-ertapenem&h1=f48a2b8300d3327d48ffb1eb98737a79dee16011b2d9930f7d4f62fb045ff893